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visit combined with extended treatment (starting 0–30 days after outpatient visit) 
with ≥ 1 of the following: a further course of intravenous corticosteroids > 7 days 
after the first course; a course of oral corticosteroids > 7 days after the intravenous 
course; intravenous immunoglobulins or plasma exchange. Algorithms for identify-
ing atypical relapses were also developed. ConClusions: General and outpatient 
ARRs are consistent between the two distinct claims databases and are similar to 
those reported in the literature. Differences in inpatient ARRs may indicate differ-
ences between clinical practices in the two systems. Further investigation in the 
real-world setting is required.
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objeCtives: Increased use of electronic medical records (EMR) has necessitated 
efficient ways to identify patients with certain clinical characteristics. This study 
compared use of standard fields and standard language recognition of progress 
notes to identify patients with metastatic lung cancer within an oncology-specific 
EMR. Methods: Lung cancer patients (ICD-9-CM: 162.2 - 162.9) with second line 
erlotinib treatment were identified from a proprietary EMR. Method 1 identified 
metastatic disease using standard data fields for diagnoses (196.x – 198.x) and/
or stage (3B/IIIB or 4/IV); Method 2 utilized keyword searches for indications of 
metastases or stage within progress notes. Chart reviews were used to confirm 
advanced disease. Positive and negative predictive values (PPV and NPV) were then 
compared across methods. Results: A total of 740 patients were identified with 
suspected metastatic disease; 60.1% (n= 448) using Method 1. Of the remaining 292 
patients, 282 (96.5%) were identified by metastases and 117 (40.1%) by stage key-
words (Method 2). Overall, 671 (86.6%) were confirmed “metastatic” with chart review 
and 5 patients excluded for evidence of other cancers. Overall, PPV was 100% and 
NPV 6.3%. Of those identified as metastatic using the standard fields, the PPV for 
metastases and stage were 65.5% and 66.3% respectively and 99.3% combined. The 
PPV and NPV among the 287 patients identified only by keyword searches, was 
98.2% and 8.7% respectively for metastases and 49.3% and 89.9% respectively for 
stage. ConClusions: Utilization of standard EMR fields for diagnosis and disease 
stage, when used together, resulted in identification of large numbers of confirmed 
metastatic lung cancer patients. However, for those patients requiring text searches 
for metastases and stage, neither separately nor in combination, could adequately 
identify metastatic disease patients. Further standardization of EMRs and consistent 
entry within oncology practices could reduce the need for labor-intensive, costly 
human chart review in real-world oncology research.
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objeCtives: Observational data derived from clinical practice is becoming increas-
ingly important to answer questions that cannot be addressed by RCTs. Although 
there are a number of administrative databases in Canada, access to more com-
prehensive, longitudinal clinical data such as smoking status, body weight and 
laboratory values in the primary care setting is limited. The objective of this study 
was to evaluate a Primary Care EMR (Electronic Medical Record) system to deter-
mine its feasibility for use in observational studies. Methods: We analyzed de-
identified patient data from primary Health Care Professionals (HCPs) including 
General Practitioners from 2009-2011. Comprehensiveness and completeness of 
each variable by visit were evaluated. First steps were taken to understand how the 
patient population compares to data from published sources. Results: There were 
3,019,954 patient visits observed by 255,274 active patients (≥ 1 visit). The patient vis-
its were entered by 497 HCPs (152 physicians). Data are available for demographics, 
vitals, smoking status, laboratory values, prescriptions, medical history, diagnosis 
(ICD-9), short term absences and referrals. Completeness of each variable by visit 
ranged from 26% for pulse to 100% for age, sex, lab results and referrals. Initial 
assessment revealed that 85.6% of written prescriptions and 88% of diagnoses were 
recorded using structured fields. The median age of patients in the EMR was 37.2 
years compared to 39.9 years reported by Statistics Canada (July 2011). Younger 
age groups were overrepresented, with the largest difference found in those 20-29 
years; no difference was observed for sex. ConClusions: The status of electronic 
primary care health records in Canada is still in its infancy. The research suggests 
this is a valuable new addition to support observational studies in Canada. Disease 
specific validation studies will be required prior to further analysis. Further research 
is being undertaken to review quality measures.
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objeCtives: The Brazilian Network for Health Technology Assessment (REBRATS) 
is composed of universities, hospitals and managing institutions who have among 
their goals the objective to elaborate and disseminate HTA information. The net-
work’s website and database are found at the http://www.saude.gov.br/rebrats and 
are tools to disseminate the policies and methodological guidelines of the network’s 
institutional organization and the studies produced by its members. To evaluate 
the degree of the network’s dissemination on national and international levels by 
analyzing the level of access and the rate of return from site users. Methods: To 
analyze the number of visits to the REBRATS site registered through the Google 
Analytics monitoring and data extraction tool, with the intention of identifying 
warrants further investigation. Robust analyses are planned to comprehensively 
describe the clinical and economic burden of TSC in the UK.
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objeCtives: To explore whether multiple sclerosis (MS) incident cohorts can be 
identified in claims databases. Methods: We used several approaches to try 
and identify MS incident cohorts in the US Department of Defense (DOD) and 
MarketScan® databases, based on diagnostic and treatment history. Patients were 
first identified with 1 year of no MS claims or treatment before their first MS 
claim. Sensitivity analyses identified patients with 1–4 years of no MS claims or 
treatment before their first MS claim. Results: In patients with a 1-year baseline 
history with no MS claims or treatment, age and baseline characteristics were 
similar to all MS patients. The mean age at index date (second MS claim) was ~50 
years, in contrast with previous research reporting a mean age at diagnosis of 
25–40 years. Patients aged ≤ 65 years with ≥ 1 MS claim and 4 years of continuous 
baseline enrolment were identified in the DOD (n= 16 444) and MarketScan® (n= 16 
352) databases. With increasing years of baseline history, more patients showed 
evidence of pre-existing MS; the percentage of total patients with no MS claim or 
treatment before the first MS claim decreased from 53.3% (1 year history) to 42.2% 
(4 years history) in the DOD database, and from 23.5% to 15.5% in MarketScan®. 
Despite the decrease in patient numbers, the mean age at index date remained 
high (44–49 years). ConClusions: Results indicate that > 4 years of patient his-
tory is needed to define an incident MS cohort in claims databases. However, the 
4-year claim and treatment-free cohort may be useful for studying treatment 
patterns and their impact on outcomes in recently treatment-naïve MS patients. 
There are substantial challenges in retrospectively identifying incident cohorts 
of MS patients using claims databases and a need for additional, large, real-world 
data sources to study newly diagnosed MS patients.
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objeCtives: Describe the patient characteristics and diabetes markers of type 
2 diabetes (T2D) patients in the newly launched IMS LifeLink Diabetes Cohort in 
France. Monitor the data quality through comparison of measures with a French 
national survey of diabetes patients (ENTRED), the UK National Diabetes Audit (NDA) 
where possible, and the “gold standard” UK Clinical Practice Research Datalink 
(CPRD). Methods: The IMS Diabetes cohort in France supplements patient-level 
data from general practitioners with additional patient data via pop-up technol-
ogy within electronic medical records to facilitate robust epidemiological studies. 
This study compares the T2D patients in the Diabetes Cohort with similar popula-
tions in terms of gender, age, disease duration, and proportion of patients meet-
ing key disease-specific targets (data presented as summary statistics). Results: 
Patient characteristics and diabetes markers were analyzed for T2D patients in the 
Diabetes Cohort (n= 5,142), ENTRED (n= 3,894), UK NDA (n= 1,909,494), and UK CPRD 
(n= 268,618). The mean (SD) age in years was 66 (12.58) in the Diabetes Cohort, 66 
in ENTRED, and 61 (15.35) in CPRD. The mean (SD) time since T2D diagnosis was 
8 (7.7), 11, and 7.7 (6.2) years in the Diabetes Cohort, ENTRED, and CPRD, respec-
tively. Mean (SD) BMI was 30.5 (5.76) in the Diabetes Cohort, 29.5 in ENTRED, and 
30.8 (6.51) in CPRD. HbA1c target level of ≤ 6.5% was met by 32.5%, 34%, 23.5%, 
and 26% of the patients in the Diabetes Cohort, ENTRED, CPRD, and NDA, respec-
tively. ConClusions: Health care systems and data collection methods vary across 
EU countries in general. Data monitoring helps assess data quality and robust-
ness. Based on comparison of patient characteristics and diabetes markers, the 
IMS Diabetes Cohort population does not appear to differ from the ENTRED popula-
tion. Although some differences between the Diabetes Cohort and CPRD data were 
noted, this unique French Diabetes Cohort appears appropriate for epidemiological 
research.
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objeCtives: To develop appropriate algorithms for identifying and classifying 
relapses among patients with multiple sclerosis in claims databases. Methods: 
Algorithms for detecting relapses in claims databases were identified by literature 
searches and refined by neurologists and database experts to identify relapses in 
inpatient and outpatient settings. Definitions were used in the US Department of 
Defense (DOD) and MarketScan® databases to determine annualized relapse rates 
(ARR) occurring after index date (date of second MS medical claim separated by ≥ 30 
days, following ≥ 12 months of continuous enrollment) during the 12-month and all 
available follow-up time. Results: A relapse was defined as an inpatient visit with 
a primary ICD-9-CM diagnosis code 340.xx or both an outpatient visit with any 340.
xx diagnosis code and oral or intravenous corticosteroid use ≤ 7 days of the outpa-
tient visit. ARR estimates in the DOD (N= 15,447) and MarketScan® (N= 35,134) data-
bases were 0.25–0.30 and 0.20–0.27, respectively. For inpatient relapses, estimates 
were 0.04–0.06 in the DOD database and 0.02–0.03 in the MarketScan® database. The 
corresponding estimates for outpatient relapses were 0.20–0.23 and 0.18–0.24. Severe 
relapses required an inpatient visit plus additional evidence of brain or spinal mag-
netic resonance imaging ≤ 7 days before or during hospitalization, or an outpatient 
